NuVision Biotherapies

NuVision Biotherapies, a medical spinout from the University of Nottingham focused on developing advanced treatments for eye conditions, has successfully raised £4.8 million in a recent funding round. This investment will accelerate the company's efforts to expand the reach of its amniotic membrane-based products, Omnigen and OmniLenz, which aim to improve healing and manage various ocular conditions.

Summary of transaction details:

• Value: £4.8 million
• Sector: Health Tech, Biotechnology, Ophthalmology
• Advisor: None mentioned
• Key Entities: Target: NuVision Biotherapies; Investors: Midlands Engine Investment Fund (managed by Mercia Ventures), University of Nottingham, Pioneer Group
• Location: Nottingham, UK

Note: This funding round underscores the continued investor confidence in innovative health tech solutions originating from academic research. The investment will enable NuVision Biotherapies to scale production, enter new markets, and bring its transformative eye care products to a broader patient base, reinforcing the growth of the life sciences sector in the Midlands.